Literature DB >> 29982998

Targeting platelet EPCR for better therapeutic factor VIIa activity.

S X Gu1, S R Lentz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29982998      PMCID： PMC6156984          DOI： 10.1111/jth.14231

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  20 in total

1.  A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.

Authors:  Geoffrey A Allen; Egon Persson; Robert A Campbell; Mirella Ezban; Ulla Hedner; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-01-04       Impact factor: 8.311

Review 2.  Endothelial cell protein C receptor: a multiliganded and multifunctional receptor.

Authors:  L Vijaya Mohan Rao; Charles T Esmon; Usha R Pendurthi
Journal:  Blood       Date:  2014-07-21       Impact factor: 22.113

3.  Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor.

Authors:  K Fukudome; C T Esmon
Journal:  J Biol Chem       Date:  1994-10-21       Impact factor: 5.157

Review 4.  Endothelial cell protein C receptor-dependent signaling.

Authors:  Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Curr Opin Hematol       Date:  2018-05       Impact factor: 3.284

5.  Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity.

Authors:  M Hoffman; Z Volovyk; E Persson; D A Gabriel; M Ezban; D M Monroe
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

6.  Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.

Authors:  Mikael Tranholm; Kim Kristensen; Annemarie T Kristensen; Charles Pyke; Rasmus Røjkjaer; Egon Persson
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

7.  FVIIa as used pharmacologically is not TF dependent in hemophilia B mice.

Authors:  Dengmin Feng; Herbert Whinna; Dougald Monroe; Darrel W Stafford
Journal:  Blood       Date:  2014-01-14       Impact factor: 22.113

8.  TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity.

Authors:  J Mahlangu; P Paz; M Hardtke; F Aswad; J Schroeder
Journal:  Haemophilia       Date:  2016-08-08       Impact factor: 4.287

9.  The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface.

Authors:  Cees Weeterings; Philip G de Groot; Jelle Adelmeijer; Ton Lisman
Journal:  Blood       Date:  2008-07-08       Impact factor: 22.113

10.  Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.

Authors:  S R Lentz; S Ehrenforth; F Abdul Karim; T Matsushita; K N Weldingh; J Windyga; J N Mahlangu
Journal:  J Thromb Haemost       Date:  2014-07-16       Impact factor: 5.824
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.